This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BioCryst Ships Flu Drug to U.S. Government: BioBuzz

BIRMINGHAM, Ala. ( TheStreet) -- BioCryst Pharmaceuticals (BCRX - Get Report) said Thursday that it shipped 10,000 courses of its intravenous H1N1 flu drug peramivir , valued at $22.5 million, to the U.S. government.

The number of peramivir courses ordered initially by the U.S. Department of Health and Human Services is lower than the maximum 40,000 courses conceived under the agency's original request submitted to the company in late September.

But the $2,250-per-course price that the U.S. government is paying to stockpile peramivir is on the high end, if not higher, than expectations.

The peramivir shipped Wednesday enters the government stockpile and will be distributed by the Centers for Disease Control and Prevention to doctors on a per-patient basis when need to treat seriously ill, hospitalized patients stricken with the H1N1 flu virus.

Peramivir is not an approved drug, so CDC is tightly controlling its distribution.

BioCryst is manufacturing another 120,000 courses of peramivir in case the government requires additional stockpiles. Under its existing contract, the government could purchase another 30,000 courses of the drug.

BioCryst shares closed Wednesday at $10.10.

-- Reported by Adam Feuerstein in Boston

Most Commented
Sirius XM Tops Targets
Most Popular
Citi Shares Hamstrung

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
BCRX $9.96 -3.77%
AAPL $132.65 1.82%
FB $81.91 0.47%
GOOG $555.37 -1.71%
TSLA $231.55 6.01%

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs